Literature DB >> 1381243

Interleukin-4 inhibits both paracrine and autocrine tumor necrosis factor-alpha-induced proliferation of B chronic lymphocytic leukemia cells.

C van Kooten1, I Rensink, L Aarden, R van Oers.   

Abstract

The proliferative response of purified malignant B cells from 26 patients with chronic lymphocytic leukemia (CLL) was investigated in vitro. In the majority of these patients, a proliferative response could be induced by the combination of tumor necrosis factor (TNF)-alpha and PMA. The concentration of PMA was found to be critical and showed a sharp optimum. In most cases maximal proliferation was obtained with as little as 0.1 ng/mL PMA. In all cases tested, TNF-alpha-induced proliferation could be inhibited completely by the addition of low doses of interleukin-4 (IL-4). Maximal inhibition was already found with 400 pg/mL IL-4. Inhibition by IL-4 was not caused by a downmodulation of TNF receptors. Apart from TNF-alpha, IL-2 was also in synergy with PMA able to induce proliferation in B-CLL cells of some patients. This IL-2-induced proliferation could be inhibited both by IL-4 and by neutralizing anti-TNF-alpha antibodies. This shows that TNF-alpha also can act as an autocrine growth factor. These data indicate that TNF-alpha is an important growth factor for neoplastic B-CLL cells and that IL-4 provides a tool to interfere with this TNF-alpha response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381243

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

1.  Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease.

Authors:  Shahryar Kiaii; Aniruddha Choudhury; Fariba Mozaffari; Eva Kimby; Anders Osterborg; Håkan Mellstedt
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

2.  Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin.

Authors:  Claudia Dürr; Bola S Hanna; Angela Schulz; Fabienne Lucas; Manuela Zucknick; Axel Benner; Andrew Clear; Sibylle Ohl; Selcen Öztürk; Thorsten Zenz; Stephan Stilgenbauer; Min Li-Weber; Peter H Krammer; John G Gribben; Peter Lichter; Martina Seiffert
Journal:  Haematologica       Date:  2018-01-11       Impact factor: 9.941

3.  Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells.

Authors:  M Lotz; E Ranheim; T J Kipps
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.